MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study
Phase of Trial: Phase II/III
Latest Information Update: 12 Oct 2017
Price : $35 *
At a glance
- Drugs Biotin (Primary)
- Indications Adrenomyeloneuropathy
- Focus Therapeutic Use
- Acronyms MD1003-AMN
- Sponsors MedDay Pharmaceuticals
- 06 Oct 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2017 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 26 Aug 2014 New trial record